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The encephalomyocarditis virus (EMCV) is a small non-
enveloped single-strand RNA virus, the causative agent of
not only myocarditis and encephalitis, but also neurological
diseases, reproductive disorders and diabetes in many
mammalian species. EMCV pathogenesis appears to be viral
strain- and host-specific, and a better understanding of EMCV
virulence factors is increasingly required. Indeed, EMCV is
often used as a model for diabetes and viral myocarditis, and is
also widely used in immunology as a double-stranded RNA
stimulus in the study of Toll-like as well as cytosolic receptors.
However, EMCV virulence and properties have often been
neglected. Moreover, EMCV is able to infect humans albeit
with a low morbidity. Progress on xenografts, such as pig heart
transplantation in humans, has raised safety concerns that
need to be explored. In this review we will highlight the
biology of EMCV and all known and potential virulence factors.
Description of EMCV
History. The encephalomyocarditis virus (EMCV) was first
isolated in 1945, by Helwig and Schmidt in Miami, FL.
1 It was
from a captive male gibbon that died suddenly of pulmonary
edema and myocarditis. Mice inoculated intravenously, intra-
peritoneally, subcutaneously, intracranially or by intranasal
instillation with filtered edema fluid from the gibbon developed
paralysis of the posterior members and a myocarditis followed by
death in a week. The pathogenic agent was at that time named the
encephalomyocarditis virus.
In 1948, a Mengo virus was isolated by Dick et al.
2 in the
Mengo district of Entebbe in Uganda. It was isolated from a
captive rhesus monkey that had developed hind limb paralysis. In
1949, cross sero-neutralization studies showed that Mengo,
EMCV were antigenically indistinct from each other, meaning
they are part of the same species. However, they were distinct
from Theiler’s murine encephalomyelitis virus (TMEV) another
cardiovirus (compare classification) that is responsible, depending
on the strain, for an acute fatal-poliomyelitis or a chronic
demyelinating disease with persistence of the virus in the central
nervous system of the mouse (for review, see refs. 3 and 4).
Classification. The EMCV belongs to the Picornaviridae
(pico = small, rna = ribonucleic acid) family, which is currently
divided into 12 genera: Aphtovirus, Avihepatovirus, Cardiovirus,
Enterovirus, Erbovirus, Hepatovirus, Kobuvirus, Parechovirus,
Tescovirus, Tremovirus, Sapelovirus and Senecavirus.
5
The genus Cardiovirus is divided into two species: the
Encephalomyocarditis virus (EMCV) and Theilovirus. The
EMCV only harbors one serotype, Mengovirus, being a strain
of EMCV. In contrast, Theilovirus comprises Theiler’s murine
encephalomyelitis virus (TMEV), Vilyuisk human encephalo-
myelitis virus (VHEV), Thera virus (TRV; isolated from rats),
Saffold virus 1–8 (SAFV; isolated from humans, for review about
SAFV see ref. 6).
5 TMEV, SAFV and EMCV share about 50%
identity.
7-9 Depending on the protein considered, the percentage
of identity between TMEV and EMCV can vary from 20 to 70%.
The L and 2A, two proteins that are considered as viral security
proteins or virulence factor, are the most divergent.
9
The EMCV characteristics and genome. The EMCV, like
other picornaviruses, is a small non-enveloped virus, with an
icosahedric capsid of 30 nm diameter
10 and a genome consisting
of a positive single-stranded RNA of approximately 7.8 kb that
allows direct translation of the RNA into a polyprotein.
The viral RNA is infectious in and of itself, meaning that viral
proteins are not required to initiate viral gene expression, and thus
its introduction by transfection into cells suffices for production of
infectious viral particles. Viral RNA acts as a mRNA during
translation and as template during genome replication. The
genome has a unique coding region flanked by two untranslated
regions (UTR). The 5' UTR is between 800 to 1,200 nucleotides
(nt) long, while the 3' UTR is about 120 nt
11 long and composed
of short stem-loop structures followed by a poly(A) tail of variable
length (20 to 70 nucleotides) (Fig.1).
The viral RNA is thus polyadenylated at the 3' end, but while
cellular mRNA are capped with a 7-methyl-guanosine, the 5'
extremity of the viral RNA is covalently linked to a 20 amino acid
viral protein called VPg (or 3B).
12 Downstream, a poly(C) tract of
about 150 nucleotides (depending on the strain) has been found
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352 Virulence Volume 3 Issue 4and is specific to aphtoviruses as well as EMCV. In contrast,
TMEV is also a cardiovirus but does not possess this poly(C)
tract.
8 Studies with Mengo virus in murine hosts suggest that the
poly(C) length may play an important role in viral pathogenesis
13
and will be further discussed in the section “virulence factor.”
Adjacent to the poly(C) tract are some pseudoknots with
unknown function. The last unit of the 5' UTR is the internal
ribosome entry site (IRES). The IRES of picornaviruses fall into
five categories, based on conserved primary and secondary
structure
14 (for review see ref. 15). EMCV has a type II IRES
of about 450 nt with a highly ordered structure made up of
hairpin loops. It is subdivided into five structural domains
designated H-L, and immediately upstream of the initiation
codon AUG a pyrimidine rich tract is found.
16 The IRES allows
ribosome binding, and thus the initiation of translation of the
open reading frame, which encodes a polyprotein of 2,292 amino
acids. Recently, the existence of a programmed ribosomal
frameshift has been described, leading to an out-of-frame
generation of a cryptic 2B* protein.
17 This finding indicates that
the EMCV genome does not have one, but at least two ORF,
encoding for 13 mature proteins. The genome of picornaviruses
also contains a higher-order RNA structure, the cis-acting
replication element (CRE), used as a template for 3D
polymerase-mediated VPg uridylation, necessary for initiation of
viral RNA replication. In the case of EMCV, the CRE is located
in the VP2 coding region and consists of a stem-loop structure
with a conserved AAACA sequence in the loop.
18
Viral proteins. The viral RNA encodes a large polyprotein
(L-1ABCD-2ABC-3ABCD) that is cleaved to produce approxi-
mately 13 mature proteins. The proteins and precursors of
EMCV as well as of the other picornaviruses get their names from
their position within the polyprotein, that is, the leader protein
(L), the precursor P1, comprising capsid proteins 1A, 1B, 1C and
1D, also called VP4, VP2, VP3 and VP1, respectively, once
integrated into the virion. The P2 and P3 are precursors of the
non-structural proteins: 2A, 2B and 2C, and 3A, 3B (also called
VPg), 2B*, the 3C protease and the RNA-dependent RNA
polymerase 3D.
11
The EMCV genome is represented in Figure1 and the
accompanying table describes EMCV proteins and summarizes, in
their respective order within the polyprotein, their known
functions. The function of the EMCV proteins have often been
assigned by virtue of their similarity to their well-studied
counterparts in poliovirus (PV), Theiler’s murine encephalomye-
litis virus (TMEV) and foot and mouth disease virus (FMDV). In
this review we highlight what has been shown for EMCV and
what has been assumed from study of other picornaviruses. (In the
next paragraphs we used the term picornaviruses to designate that
as far as we know it has not been clearly proven for EMCV but it
has been shown for other picornaviruses.)
Three-dimensional structure of the capsid. The Mengovirus
has been crystallized and analyzed by X-ray diffraction.
10,19 The
viral capsid is organized into an icosahedron with exactly 60
copies of each of the structural protein. The basic unit of the
capsid is a protomer formed by the association of VP1, VP2,
VP3 and VP4. The VP4 protein is located in the internal face of
the capsid and interacts with the viral RNA. Five protomers
assemble into a pentamer and 12 pentamers are necessary to
form the capsid. The capsid is organized around symmetric axes
of 2-, 3- and 5-fold symmetry. Five VP1 proteins are grouped
around the 5-fold symmetry axis, while VP2 and VP3 proteins
alternate around the 3-fold symmetry axis. In the case of Mengo
and TMEV the five copies of VP1 form a plateau with a five
branches star shape. The extremities of the branches are
constituted of prominent structures (loops) that are the most
exposed region at the surface of the Mengo capsid. Each branch
of the star is separated by a depression called the pit. The pit
corresponds to the contact region between VP1 and VP3. The
pit is considered as the analog of the “canyon” found on the
capsid of PV. By analogy, it has been supposed that the Mengo
pit would serve as a receptor binding site. To support this
hypothesis, residues lining in the pit are more conserved
than other surface residues
20 and computer modeling can
fit a sialic acid residue into a pocket near the bottom of the
22-Å-deep pit.
21
Viral Cycle
The EMCV viral cycle, represented in Figure2, is detailed below.
(The time scale given in the figure legend is specific for BHK-21
and might vary upon the cell type and the EMCV strain use for
the infection.)
Adsorption: entry. To initiate the infection, the first step is the
attachment of the virus particle to a cell membrane molecule: a
receptor or coreceptor.
21 This virus-cell interaction and the
distribution of the virus receptor are considered to be determinant
for the viral host range, tissue tropism and pathogenesis. Vascular
cell adhesion molecule 1 (VCAM-1) is a sialoglycoprotein that
has been identified as a receptor for EMCV on murine vascular
endothelial cells.
22
Another 70 KDa sialoglycoprotein found on HeLa and K562
cells and the Sialylated glycophorin A (found on red blood cells)
have also been described as being attachment proteins for
EMCV.
23,24 Sialoglycoproteins are “sticky” proteins that may
have non-specific binding properties. Thus, the main receptor for
EMCV, as well as its viral binding partner, remains uncertain. A
recent study suggests that the capacity of the virus to interact with
cell surface sialic acid residues is important for infection of BRL
cells.
25 However, it is interesting to note that sialic acid binding is
not required for all EMCV strains.
26
Figure1 (See opposite page). (A) Genomic organization. The EMCV genome is a positive single-strand RNA, covalently linked to the viral protein VPg in
5’. The genomic RNA is composed of two UTR in 5’ and 3’ and an ORF that encodes for a polyprotein (dark gray). The polyproteins is cleaved by the 3C
protease, cleavage sites are indicated (black triangles). Ribosome skinping (curved right arrow). A second ORF (clear gray) due to a +2 ribosome
frameshifting. cre, Cis replicating element; PKs, pseudoknots; IRES, internal ribosome entry site. (B) Description of EMCV proteins properties and functions
known or assumed by similarity with other picornaviruses.
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cardioviruses are poorly documented. It is known that infectivity
of EMCV and PV does not require diminution in pH. Thus,
unlike FMDV whose entry requires receptor-mediated endo-
cytosis and endosomal acidification, it is believed for EMCV that
interaction of the viral particle with a cellular receptor suffices to
induce the conformational changes of the capsid shell required for
viral RNA delivery into the cytoplasm.
27,28 These conformational
changes has been shown for PV to affect contacts between
pentamers and thus initiate the dissociation of the capsid. VP1
N-terminal extremities have an amphipathic helix that inserts into
the cell membrane and allows the formation of a pore through
which the viral RNA is thought to be injected into the cell.
28
However this two-steps dissociation process seems not to fully
apply to cardioviruses since contacts between their pentamers are
less extensive than for PV.
21 Thus it is still unclear how EMCV
release its genome into the cytoplasm.
Translation. Once the genomic RNA is in the cytoplasm, it
must be translated as it cannot be replicated by cellular RNA
polymerases and no viral enzymes are brought along with the viral
particle. The 5' end of the positive single-stranded viral RNA is
not capped, but is linked to the VPg viral protein. This VPg does
not have any known role in translation and can be detached from
the viral RNA by a cellular enzyme.
29 The genome is then
Figure2. Encephalomyocarditis viral replication cycle. The virion binds to a cellular receptor. After uncoating, the genomic RNA is released by an
unknown mechanism. Internalization (~1–2 h). Once in the cytoplasm, the VPg protein is detached to the 5’ end of the genome, the translation is
initiated at the IRES that require the PTB cellular protein, the polyprotein is synthesized. Translation (~2.5–3 h). The polyprotein is cleaved during and
after the translation, leading to precursors or mature proteins. Some of those proteins allow formation of the membranous vesicles where genome
replication will occur. The positive genomic RNA is replicated into negative RNA thanks to the VPg-pUpU that serves as a primer for the 3D polymerase.
The negative RNA syntesis leads to the production of a double stranded RNA molecule, the replication form (RF). The newly synthesized negative RNA in
turn, serves as templates for synthesis of positive RNAs in the replication intermediate (RI). Replication (~3–4 h). Those new positive genomic RNAs will
either serve for translation after removal of VPg, serve as matrix for synthesis of new viral RNAs or will be encapsidated. The viral capsid proteins VP0, VP1
and VP3 auto-assemble into a protomer. Five protomers will assemble into pentamers and 12 of them will form the icosahedric capsid. Encapsidation
(~4–6 h). After RNA encapsidation, cleavage of the precursor VP0 into VP2 and VP4 allows maturation of the virion. Virions are then egress by cell lysis.
Egress (~6–10 h). (Modified from ref. 177).
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the production of new viral particles. For EMCV, initiation of
translation is cap-independent due to its IRES. There exist five
types of IRES that differ in their primary and secondary struc-
tures, the location of the initiation codon and their activity in
different cell types. All picornaviruses possess an IRES. EMCV
and the other cardioviruses have a type II IRES (like the aphto-
viruses, but unlike the enteroviruses that has a type I IRES).
30
The EMCV IRES requires binding of cellular factors, including
all the eIFs, except eIF4E, the N-terminal region of eIF4G and
the polypyrimidine tract binding protein (PTB).
31,32 This then
allows direct recruitment of the 40S ribosomal subunit together
with several translation initiation factors (eIF-1A, eIF-GTP-met-
tRNA and eIF3), which permits direct initiation of translation at
the start codon. Unlike cap-dependent translation, IRES
translation does not require eIF4F complex formation; that is,
binding of the eIF4E component to the cap structure at the 5'
mRNA and subsequent recruitment of the 40s ribosomal subunit,
which scans the 5' non-coding region until the authentic start
codon is reached. In both cases, the 60S ribosomal subunit joins
the complex at the AUG initiation codon, initiation factors are
released, and elongation ensues.
The translation of picornaviral RNA leads to synthesis of viral
proteins, some of which inhibit cap-dependent translation.
Enterovirus 2A
pro cleaves eIF4E, a function assumed by the L
pro
for aphtoviruses. The cardioviruses that possess only one
protease, 3C, seem to have developed different strategies that
enable inhibition of host cell translation, even if this inhibition is
slower and less efficient.
33 The EMCV 2A protein is believed to
play an essential role in this process (see Fig.3 and below the
description of “EMCV 2A protein” in the section “EMCV
Virulence”).
Figure3. Encephalomyocarditis viral 2A protein. (A) EMCV 2A protein organization and putative sequence. (B) Functionality of EMCV 2A protein and
potential consequence on EMCV virulence.
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formed by the 3C protease (3C
Pro) of EMCV. However, the first
instance of polyprotein processing is not proteolytic, and indeed
occurs during translation between the 2A and 2B protein, before
EMCV 3C
pro synthesis. The NPG(P) sequence at the junction
between these two proteins leads to ribosome skipping; no peptide
bond is made between the glutamine (G) of 2A and the proline
(P) of 2B, resulting in production of two separate peptides (for
details see Fig.3 and description of the 2A protein in the section
“EMCV Virulence”).
EMCV 3C
pro, the only protease of EMCV, is an essential
protein. It is a cysteine protease that exhibits a high degree of
substrate specificity. Comparison of known cleavage sites of the
EMCV viral protease has failed to reveal a clear consensus
sequence, although some common determinants can be identified.
EMCV 3C
pro preferentially cleaves between Q or E and G, S or A
residues.
34,35 The precursors 3ABC, 3CD and P3 of EMCV are
able to cleave as efficiently as the 3C.
35 Of note, 3CD of EMCV
can cleave P1, whereas 3CD of PV cannot.
EMCV 3C
pro has been described to be extremely labile in vitro
and in vivo. An LLVRGRTLVV amino acid motif has been
identified as a destruction signal that leads to 3C ubiquitination
and degradation by the proteasome.
36-38 In contrast to FMDV and
PV, only one cellular substrate has been reported for the EMCV
3C
pro. Interestingly, EMCV 3C
pro is able to cleave the RNA
recognition sensor RIG-I, at least in vitro.
39 This finding could
explain why RIG-I is unable to sense EMCV RNA.
During EMCV infection, once the 3C protease is translated, it
is immediately active and starts to cleave the polyprotein in
cis. When detached from the polyprotein, 3C
pro can also
cleave newly synthesized polyproteins in trans. EMCV 3C
pro
cleavage sites within the polyprotein are indicated by small black
triangles in Figure1. The last cleavage occurs during the
maturation of the virion, after RNA encapsidation, when VP0
is cleaved into VP4 and VP2 (see paragraph “provirion
assembly—encapsidation”).
Replication. Localization-formation of the membranous
replication complex. Replication of the picornavirus genome
occurs within the cytoplasm. Picornavirus infection leads to
intracellular membranous proliferation and rearrangements. The
endoplasmic reticulum (ER) and Golgi apparatus are rearranged
and the cytoplasm fills up with bilayer membranous vesicles.
40
Viral replication takes place at the vesicle surface.
41 The 3A and
2BC proteins of PV are known to localize in the ER and are
sufficient to induce the formation of these vesicles.
The enterovirus 2B protein is a small hydrophobic protein. It is
localized in the ER and the Golgi and reduces Ca
2+ levels in these
organelles. The 2B protein is a viroporin,
42 able to form
transmembranous pores, which could explain this calcium flux.
In addition to membrane rearrangements, it inhibits protein
trafficking through the Golgi complex.
43-46 The role of the 2B
protein has not been clearly established for EMCV. However,
De Jong et al.
44 showed that the 2B protein of EMCV (like that of
FMDV) shares little similarity (, 20% sequence identity) with
the enterovirus 2B proteins, which are much smaller. The 2B
protein of EMCV contains one or more hydrophobic regions, but
no cationic amphipathic a-helix like that found in all enterovirus
2B proteins. Although EMCV 2B, when lowly expressed in cells,
does not show a clear ER localization, it was also found to reduce
the level of Ca
2+ in the ER but not the Golgi.
44 The mechanism
underlying this decrease is unknown, and the localization of the
2B protein has yet to be confirmed in the context of an EMCV
infection. In the same study, the 2B protein of EMCV and
FMDV, unlike the 2B protein of enteroviruses, was shown to be
unable, on its own, to interfere with protein trafficking.
In addition, the 3A protein, which is a small transmem-
braneous hydrophobic protein, has also been found in the
membranous complex. While the Enterovirus 3A protein inhibits
ER-to-Golgi transport, it has been demonstrated that the 3A
protein of FMDV, TMEV and EMCV does not.
47,48 Thus,
EMCV 3A and EMCV 2B do not block protein transport. It
remains to be established whether EMCV has the capacity to
block the transport form the ER to the Golgi. Indeed, expression
of 2BC or 2B and 2C together are required to block ER-to-Golgi
apparatus transport in FMDV infected cells.
49,50 However, it has
been described that 2BC of TMEV, when express from a plasmid,
does not show the same pattern of localization as 2BC of
FMDV.
51 In conclusion, it is yet to be determined whether
protein trafficking is inhibited during EMCV infection. To our
knowledge, there is no evidence regarding inhibition of ER-to-
Golgi protein trafficking in EMCV-infected cells. Of note, even if
EMCV does not inhibit ER-to-Golgi trafficking, it induces
intracellular membranous proliferation and rearrangements.
52,53
It is assumed that the lipids that make up the membranous
vesicles are derived from the ER.
46 However, those vesicles might
also originate from the autophagic cellular pathway. Indeed,
during PV infection, it has been shown that the vesicles of the
replication complex resemble those of the autophagic pathway, in
that they possess double membrane structures, cytoplasmic
components within the vesicles, and typical autophagic markers
such as LC3 and LAMP1 (latency-associated membrane protein
1).
40,54 Very recently, similar observations have also been described
for both EMCV and FMDV. During EMCV infection,
colocalization of the 3A and VP1 proteins with LC3 at the surface
of double-membrane vesicles has been described.
52 Colocalization
of 2B, 2C and 3A viral proteins of FMDV with LC3 and LAMP1,
as well as colocalization of VP1 with Atg5 (cellular protein required
for autophagosome formation), has been reported.
53 Some studies
showed that inhibition of autophagy led to a decrease in EMCV
production whereas its induction with rapamycin led to an increase
in viral titer.
52,55 This suggests that the autophagic pathway
may be hijacked by EMCV, as other picornavirus, to furnish a
membranous support for viral replication.
54
Thus, viral replication of EMCV is believed to occur in the
cytosol within the replication complex localized at the surface of
clustered membranous vesicles. The replication complex is
essentially composed of the viral RNA-dependent RNA poly-
merase 3D
pol in association with the 3C
pro, the 2C and the 3AB
proteins.
Again, very few studies have addressed the replication of
EMCV, and most of our assumptions are based on extrapolation
from studies performed with enteroviruses. The model developed
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viruses, but this awaits confirmation.
Negative strand RNA synthesis. It is commonly accepted that
translation of picornaviruses must stop to allow transcription of
the negative strand viral RNA,
56 negative RNA synthesis being the
first step of viral RNA replication. The mechanism governing the
shift from translation to replication is not fully determined,
although a model has recently been proposed for PV.
57 This
model implicates cleavage of the host protein PCBP2 by 3CD
pro;
however, as this cleavage has never been described for EMCV,
further studies will be required to decipher how the transition
from translation to replication may occur during EMCV
infection.
The initiation of negative strand RNA synthesis of picorna-
viruses is still controversial. A model for PV proposes that such
initiation starts with the circularisation of the genome through the
interaction of the cellular protein PCBP [poly r(C) binding
protein] with the 3CD protein, which itself binds to the cloverleaf
structure of the 5'UTR viral genome.
58 For EMCV these
interactions might take place at the S fragment or the poly(C).
Thus 3' and 5' viral genome extremities may temporarily interact
via a protein bridge that forms the so-called ribonucleoproteic
complex. The formation of this initiation complex permits the
uridylylation of the VPg (3B) by 3D
pol using the poly(A) tract or
the AAACA motif of cre as a template.
The cre is an RNA stem-loop structure of the viral genome,
found in the VP2 coding sequence of EMCV.
18 The loop bears an
AAACA, the two first A residues of which acting as a template for
the synthesis of VPg-pU and VPg-pUpU (uridylylation) and
therefore for the initiation of replication.
59 Mutation within this
conserved motif causes a marked decrease in viral replication.
Interestingly, the position of the cre within the genome seems not
to be critical and can even be provided in trans.
18,60 It is believed
that VPg-pUpU matches with the poly(A) 3' extremity and
therefore acts as a primer for negative RNA strand synthesis by
3D
pol. The elongation of the negative strand leads to the
formation of a double-stranded RNA structure called the
replication form (RF).
61 After RF formation, synthesis of new
positive RNA can start.
Positive strand RNA synthesis. Picornavirus positive strand
synthesis initiation from the RF has not been elucidated. Two
main hypotheses have been proposed for VPg-pUpU generation.
The first hypothesis suggests that initiation of positive strand
synthesis may use VPg proteins that have already been
uridylylated, in excess, during negative strand synthesis.
62 The
second hypothesis proposes that VPg-pUpU is generated at the
poly(A) tail of the positive RNA for the synthesis of the negative
strand, while the uridylylation at the cre is essentially used for
positive strand synthesis.
63
The RF structure is presumed to be unwound for positive
strand synthesis. The 2C viral protein possesses an ATP
ase activity
and a putative helicase domain (even if helicase activity has never
been reported), and seems to be important for positive RNA
synthesis.
64 It has been reported that the 2C protein binds to the
3' extremity of the negative strand RNA along with the cellular
p38 protein. This interaction probably destabilizes the RF.
However, cellular helicases and nuclear proteins might also be
implicated, as the RF structure is infectious when used to transfect
non-enucleated cells.
61,65
The negative strand RNA newly synthetized is then used as a
template for positive strand RNAs. Indeed, there is formation of
partially double-stranded RNA, corresponding to the replication
intermediates (RI) that allows simultaneous synthesis of several
positive RNA strands from a single negative RNA template.
Provirion assembly: encapsidation, viral release or egress. The
last steps in the EMCV viral cycle are encapsidation of newly
synthesized viral RNA, maturation of the provirions and virus
release from the cell. The mechanisms involved in encapsidation
and maturation are still unresolved and are probably the least
studied steps of the viral cycle.
The formation of viral particles occurs in the cytosol through
the 3C
pro cleavage of the P1 precursor, releasing VP0, VP1 and
VP3 that auto-assemble to form a protomer containing a single
copy of each protein. Five protomers form a pentamer and 12
pentamers auto-assemble to form the icosahedric capsid. There are
two models for picornavirus RNA encapsidation. A first model
proposes that the protomers assemble into empty capsid and that
the viral RNA is then inserted into the capsid. This is supported
by the observation that empty capsids are found during
picornavirus infection, but has never been formally proven. A
second model proposes that the pentamers assemble directly
around the neo-synthesized viral RNA. Picornaviruses encapsidate
only positive single-stranded RNA linked to the VPg protein.
66 In
addition, only newly synthesized RNAs are encapsidated,
suggesting that a link exists between active replication and
encapsidation.
67
Substitution of P1 by a reporter gene in several picornaviruses
does not perturb viral RNA encapsidation when capsid proteins
are provided in trans.
68-70 This indicates that the putative
encapsidation signal is not found within the P1 region of viral
RNA. In fact, numerous attempts to identify an RNA
encapsidation signal have failed. A single study reports that the
encapsidation signal could lie within the 5'UTR of the Aichi virus
together with the L protein.
71,72 However, a recent paper, which
tends to favor the second model of encapsidation, also proposes a
mechanism by which the triple interaction vRNA-2C-VP3 would
be sufficient to explain the specificity of picornavirus encapsida-
tion.
73 The novel mechanism described by Liu et al. suggests that
encapsidation takes place at the site where newly synthesized
genomes emerge from the replication complex, since morpho-
genesis is linked to genome replication, 2C ATP
ase being a
component of the replication complex and possessing specific
affinity for the VP3 capsid protein. They showed that for chimeric
viruses composed of PV and Cox that are unable to support
encapsidation, the encapsidation process could be restored if the
P1 and 2C proteins originate from the same virus. Previous
studies on heterologous encapsidation
68 have shown that the PV
replicon could be encapsidated into coxsackie B3 virus (CBV3),
human rhinovirus 14 (RHV14) and mengovirus capsids. It should
be noted that the capsid proteins were provided by the expression
of the full viral cDNA under control of a T7 promoter, indicating
that their 2C proteins were certainly present.
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maturation step in which VP0 is cleaved into VP2-VP4. This
cleavage is considered to be autocatalytic and would result from a
local activation of water molecules by a His residue in the VP2.
This would lead to a nucleophilic attack on the scissile bond and
cleavage.
74,75 The maturation is necessary for the generation of
infectious viral particles. Indeed, it is possible that VP0 cleavage is
required for the subsequent release of viral RNA into the
cytoplasm of newly infected cells.
76
EMCV is a rapidly lytic virus that causes necrotic cell death
within 7 to 10 h.
77,78 However, just what may lead to membrane
permeabilization and what the signals for cell lysis and viral
egress may be remain to be characterized. Several hypotheses
have been advanced, such as cell burst due to accumulation of
viral particules or proteins in the cell or permeabilization of cell
membranes due to viroporins (like the 2C of PV). Irrespective of
which process is involved, the efficiency of viral release is likely to
influence EMCV virulence (further developed in the section on
EMCV Virulence).
Host Spectra, Epidemiology and Zoonotic Potential
EMCV was first isolated from a gibbon in 1945 in Florida,
1 and
then from swine following an epizootic in Panama in 1958.
79
From 1945 to the present, EMCV has been detected in many
wild and domestic animals, in many different areas around the
world, such as Europe,
80,81 Canada,
82 South America,
79,83,84
Australia,
85 Korea
86 and China.
87
A non-exhaustive list of animals from which EMCV has been
isolated includes voles, squirrels, elephants, swine, wild boar,
racoons, antelope, lions, birds and several species of non-human
primates.
1,81,85,88,89 Human infections have also been reported (see
paragraph on zoonotic potential).
All together these studies indicate that EMCV has a worldwide
distribution and can infect a wide range of animal species. Its
natural reservoir is thought to be rodents (mouse or rats). Indeed
rat infections are usually asymptomatic and the virus can replicate
and be excreted up to 29 d post-infection.
90 The presence of
infected rodents in proximity to farms with infected swine also
suggests they play an important role in virus spread,
91,92 even more
so because horizontal transmission between pigs seems limited.
93
However, a study performed in Greece points out that the
possibility of a reservoir existing in wild boar should not be
neglected.
88
EMCV infection occurs by ingestion of EMCV-contaminated
food, water and diseased carcasses.
89,94 EMCV is a small non-
enveloped virus that is very resistant and may remain infectious
for days, even in a hostile environment. EMCV is quite stable in a
large spectrum of pH and resistant to ether treatment.
Disinfection methods recommended by veterinary are multiples:
the virus can be inactivated by treatment at 60°C for 30 min,
H2O containing 0.5 ppm of chlorine, iodine-based disinfectants
or mercuric chloride.
95 Recently, a non-invasive and environment-
friendly method using a femtosecond laser has been proposed to
inactivate the virus.
96 A large scale usage and its extension to other
pathogens could be an interesting development for this method.
Zoonotic potential. The EMCV has often been described as a
potential zoonotic agent. Nevertheless, an association between
human infection and disease has still not been clearly established.
Some experimental infections on human explants or human
primary cell cultures have been described and clearly point out
that human cells are sensitive to EMCV.
97,98
Between 1940 and 1950 childhood infections associated with
fever and encephalitis but no myocarditis were described in
Germany and Holland. Several EMCV strains (MM, AK, Li32,
Ortilb and SVM) were isolated after inoculation of rodents.
99
However, the assignment of these strains to the EMCV species
was determined on the basis of serological tests, without
virological confirmation. Unfortunately, these strains are no
longer available for further characterization. In an earlier study,
neutralizing antibodies against EMCV were found in 17 soldiers
based in Manila, Philippines. These soldiers presented febrile
illness for 3 d. Three patients out of the four presented an increase
in neutralizing antibody titer.
100 In 1948, after isolation of a
Mengovirus from a Rhesus monkey, a researcher who was
studying the virus and taking care of the animal had developed
encephalitis, from which he later recovered. Meanwhile, the virus
was isolated from his blood.
101
From 1950 to 2009, no EMCV infections associated with
clinical signs were reported. However, serological studies
performed on healthy persons revealed a prevalence of 2.3% to
15%.
102-104 In Austria, a more recent study revealed that 5% of
persons with occupational exposure to animals were EMCV
seropositive. This percentage reached 15% for hunters.
105,106
Two recent studies, performed in Peru, described human cases.
Patients presented febrile illness, likely due to EMCV infection.
Indeed, virus was isolated during the acute phase for two patients
with nausea, headache and dyspnea. Upon molecular diagnosis,
no virus other than EMCV was detected.
84 Isolation of viruses
from sera of acute phase patients supports the idea that EMCV
can infect humans and cause disease. A wider study has been
performed and indicates that EMCV could be responsible for
almost 1% of the febrile illness analyzed during this study in
Peru.
83 Despite the low morbidity, human exposure to the virus is
quite common. Indeed, 6% to 17% of Peruvian town inhabitants
are seropositive for EMCV.
83 These recent data confirm what
R. Tesh said in 1978: “EMC infection in man is fairly common
but most human cases are probably asymptomatic and/or
unrecognized.”
102
EMCV Pathogenesis
EMCV infection occurs by ingestion of EMCV-contaminated
food, water and diseased carcasses.
89,94 EMCV is a small non-
enveloped virus that is very resistant and may remain infectious
for days, even in a hostile environment. There is considerable
variation in the severity and location of lesions caused by EMCV
in the broad range of susceptible hosts. However, EMCV
pathogenesis has mostly been studied in rodents, swine and
monkeys.
General symptoms in non-human primates, such as baboons,
gibbons, chimpanzees, green and rhesus monkeys, are mainly
358 Virulence Volume 3 Issue 4death and labored respiration associated with acute heart failure.
The salient necropsy findings are pulmonary congestion and
edema, hydropericardium, hydrothorax, ascites, lymph node and
splenic hypertrophy, and pale white-to-tan mottled hearts.
Placental infection with fetal loss can also occur.
107 Sub-cutaneous
inoculation of baboons or African green monkeys induces
myocardial and nervous disorders leading to death within a week.
Infection of monkeys can lead to high mortality in primatology
centers, as occurred in a baboon colony in San Antonio in
1992,
107 and more recently in a group of rhesus macaques.
108
Histologically, affected myocardiums present multifocal infiltra-
tion by lymphoplasmacytic cells admixed with necrotic and
degenerate myofibers and infrequent mineralization.
108
In pigs. EMCV usually induces acute focal myocarditis with
sudden death in pigs. Myocarditis is characterized by cardiac
inflammation and cardiomyocyte necrosis. Other symptoms have
been observed, such as anorexia, apathy, palsy, paralysis or
dyspnea.
109 Susceptible pigs develop severe myocarditis followed
by sudden death, while more resistant pigs develop mild
myocarditis and can remain asymptomatic. Experimentally
infected piglets show high fever, followed by death within 2 to
11 d, but can sometimes recover with chronic myocarditis.
Mortality in piglets before weaning can rise to 100%. Mortality
decreases with age.
91
After oro-nasal infection of piglets, viruses are thought to
spread from tonsils to target organs by means of infected
circulating monocytes.
110 In swine, the heart is considered to be
the major target organ.
110 A few days after infection, however,
viruses can be isolated from many other organs, such as brain,
spleen, intestine, pancreas, liver, kidneys, heart, lungs and lymph
nodes.
91,109,111 Upon autopsy of experimentally infected piglets,
myocardial lesions, hydropericardium, pulmonary edema, ascites
and hydrothorax are observed.
109,110 Hearts are often dilated and
show focal areas of necrosis (with uneven greyish white
discoloration). The virus can be detected in the myocardium,
even when myocardial lesions are small or absent.
109,110
Histological analysis of piglet hearts reveals myocarditis
associated with scattered or localized infiltration and accumulation
of mononuclear cells, vascular congestion, edema and myocardial
fiber degeneration, with necrosis. In the brain, congestion is
accompanied by meningitis, perivascular infiltration of mono-
nuclear cells and neuronal degeneration.
112,113
Reproductive disorders including abortion, fetal death or
mummification have been described in infected females.
114
In rodents. EMCV infection can be asymptomatic,
90 but in
mice generally induces encephalitis,
115 member paralysis,
78,116-118
myocarditis
119 or type 1 diabetes.
120 EMCV infection can also lead
to reproductive disorders in pregnant mice,
121 testicular lesions
(orchitis) in mice
122 and also to lesions in salivary and lachrymal
glands (sialodacryoadenitis) (for review see ref. 123).
Susceptibility to EMCV infection differs according to the strain
and age of mice, and the viral strain and dose of inoculum. Infection
of mice with different EMCV strains results in a wide spectrum of
clinical manifestations, ranging from inapparent infection to severe
disease and death.
119 For instance, the D strain of EMCV induces
diabetes, whereas the M strain triggers myocarditis.
Myocarditis in mice. EMCV-induced myocarditis is
characterized by myocardial necrosis and cellular infiltration. It
has been widely used as a model to study viral-induced
myocarditis. Many studies seem to indicate that the
inflammatory response is deleterious,
124-128 but discordant data
do exist.
129 In recent years studies have shown that mast cells also
play a critical role in the progression of heart failure induced by
EMCV in mice.
124,125 (This will be further discussed in the section
dealing with EMCV virulence).
Hind limb paralysis and encephalitis. Hind limb paralysis and
encephalitis have been documented during EMCV infection. This
indicates that the murine central nervous system (CNS) is
attained and damaged during EMCV infection. Upon
administration of a high dose of inoculum, mice show
encephalitis and paralysis within 4 d of infection and no
recovery.
78 Cerebral lesions are mainly perivascular mononuclear
infiltrate in the form of perivascular cuffs, multifocal neuronal
necrosis and diffuse gliosis
78,117,130 and are predominantly located
in the hippocampus.
78,117 EMCV also induces spinal cord lesions
comprising focal degeneration, lymphocytic infiltration, mild
neuronal necrosis and demyelinisation.
78,118,131,132 Inoculation of a
low dose of virus leads to a biphasic hind limb paralysis with
possible recovery.
131 EMCV, unlike TMEV and JHL, does not
lead to persistent infection of the brain. Hind limb paralysis and
demyelinisation occurring during EMCV infection have been
proven to be partly due to infiltration of macrophages and
lymphocytes
131,132: treatment of mice with antibodies raised
against macrophages, CD4
+ and CD8
+ T lymphocytes was
sufficient to limit the development of the paralytic syndrome and
reduced lesions in spinal cords, indicating that these cell types
may participate in CNS injury.
133,134 In addition, a study
demonstrated that after intracranial inoculation of EMCV,
oxidative damage to neurons was due to the induction of
NADPH oxidase in microglia (brain macrophages).
135 Thus it
seems that inflammatory and immune responses are deleterious
for the host CNS tissues.
Diabetes. Infection of genetically susceptible mouse strains with
a high dose of EMCV (D) leads to diabetes within 3 to 4 d. This
diabetes seems to be mainly due to acute destruction of pancreatic
β cells by viral replication without involvement of the immune
system. By contrast, during infection with a low dose of EMCV, it
was found that the immune system, especially macrophages, plays
a central role in the destruction of pancreatic β cells.
136
Inactivation of macrophages prior to viral infection completely
prevents EMCV-induced diabetes.
137 It appears that upon low-
dose infection of mice the virus initially replicates in pancreatic β
cells, leading to the recruitment of macrophages that are activated
at the pancreatic islets. These activated macrophages produce
soluble mediators like interleukin-1 β (IL-1 β) and produce TNFa
and nitric oxide (NO), which induce apoptosis in β cells (for
review see ref. 120).
EMCV Virulence
As described in the previous section, EMCV is known to induce
myocarditis, diabetes and reproductive and nervous disorders. It is
www.landesbioscience.com Virulence 359believed that symptoms and disease are viral strain-specific.
Animal species, sex and age are also known to be important factors
for EMCV virulence. Few molecular determinants of EMCV
virulence have been defined so far. This chapter will describe them
and highlight what should be considered to be potential factors in
EMCV virulence.
Adsorption and entry. The first primordial steps that can
modulate EMCV virulence is the ability of the virus to adsorb to
the cell and gain entry. The viral capsid proteins, in their capacity
to interact with cellular receptors, are crucial for this entry step
and may be considered to be factors that can modulate EMCV
virulence. Indeed, mutation of a single amino acid (alanine 776)
of the EMCV polyprotein (in the VP1 capsid protein) of a
diabetogenic EMCV renders this virus non-diabetogenic. This
mutation modifies the native protein conformation of VP1, and
thus inhibits virus attachment to the pancreatic β-cell receptor.
Indeed, the Ala776 plays a crucial role in promoting viral
infection and destruction of β cells, thereby inducing devel-
opment of diabetes. As regards diabetes induced by EMCV, the
genetic background of the mouse is also an important factor.
138
An autosomal recessive gene has been described to modulate the
level of expression of the viral receptor at the surface of the
pancreatic β cells, and seems to be responsible for mouse
susceptibility.
139 In this regard, it has been established that SJL/J
mice are susceptible to EMCV-induced diabetes while C57BL/6
mice are not. This discrepancy has most commonly been
attributed to a lower level of expression of the viral receptor at
the surface of β cells of C57BL/6 mice.
138 Indeed, only certain
strains of mice such as SJL/J, SWR/J, DBA/2J and NIH/Swiss
develop diabetes, while strains such as C57BL/6J, AKR/J, CBA/J,
LP/J and CE/J do not.
138
Zhu and colleagues recently observed that mutation of the
threonine at position 100 of the VP1 protein decreases the
neurovirulence of EMCV.
140 This is the first report indicating that
a mutation in the viral capsid protein could attenuate its
neurovirulence. Substitution of the Thr100 with an isoleucine
or a proline reduced the ability of EMCV to grow in the brain of
infected mice. The mutants induced only moderate inflammatory
responses and less brain damage, but still caused mortality when
inoculated at high doses.
The VP1 Thr100 mutation is not as deleterious for EMCV
neurovirulence as the mutation in the Ala776, which is
determinant for EMCV infection of pancreatic β-cells and gain
or loss of diabetogenicity. The role played by the VP1 Thr100
amino acid is unclear and other factors may determine EMCV
neurovirulence.
Thus, the VP1 protein of EMCV influences virulent properties,
because it is structure by which the virus attaches to its cell
receptor and is essential for virus adsorption and entry. However,
it should be noted that mutations within viral capsids may also be
deleterious for viral assembly as well as release. Indeed, delay in
viral release could probably be sufficient to attenuate virulence.
78
The length of the EMCV poly(C) tract. The length of the
EMCV poly(C) tract has been suspected to be important for
Cardiovirus virulence. It has been clearly demonstrated that
diminution of the length of the Mengovirus poly(C) strikingly
attenuated its virulence, rendering it non-pathogenic in mice.
13,141
Of note, a Mengovirus harboring a short poly(C) tract has been
investigated as a potentially safe vector for live recombinant
vaccines.
141 Studies of different Mengo and EMCV viruses have
indicated that virulence of these viruses in mice seems to be
positively correlated with their poly(C) tract length, even if short-
poly(C) EMCV strains were attenuated only slightly if at all
compared with Mengovirus.
142 Thus, a short poly(C) is less
deleterious for EMCV strains.
142 Indeed, virulent EMCV strains
with very short poly(C) tracts have been described. LaRue et al.
117
isolated an EMCV strain exhibiting a short poly(C) tract (7 to 10
nt) that was pathogenic in mice, pigs and cynomolgus macaques.
The fact that a short poly(C) tract is less deleterious for EMCV
strains than for the Mengovirus strain indicates that the viral
genomic context might influence the degree to which virulence is
dependent upon the length of the poly(C) tract.
Viral strain sensitivity to the poly(C) tract length is suspected to
be due to a defect in viral replication in certain cell types.
143 How
exactly the length of the poly(C) tract may interfere with viral
replication remains to be clarified.
2B*. Very recently, Loughran et al.,
17 demonstrated the
existence of a programmed ribosomal frameshift that leads to the
translation of a cryptic protein of 129 amino acids, called 2B*
(represented in Fig.1), which had been previously unknown.
These findings indicate that the EMCV genome does not have a
single ORF but two and encodes not 12 but rather 13 mature
proteins. The 12 N-terminal amino acids of the 2B* protein are
identical to those of 2B, and then the +2 frame shift occurs at a
conserved GGUUUUU motif. By introduction of synonymous
mutations within the conserved motif, the authors showed that
inhibition of ribosomal frame shifting and/or absence of 2B* led to
a virus with a reducedplaquesize phenotype.Importantly,theyalso
observed that efficient frame shifting was only observed in virus-
infected cells, indicating that it might be a process “programmed”
by the virus. They did not, however, address whether the wt
phenotype is restored if ribosomal frameshifting is prevented but
expression of the 2B* maintained. It would be of interest to
determine whether synthesis of the 2B* protein is important or
whether it is the ribosomal frameshifting itself. This process could
be important inregulatingvirus geneexpressionand mayplaysome
sortof regulatory role inthevirallifecycle. Itwouldbeinteresting to
determine whether 2B* plays a critical role in EMCV virulence.
The L protein. The L protein has been termed a “viral security
protein” that is nonessential for virus replication but has evolved
to fulfil functions that are conserved among picornavirus. The
main function of viral security proteins is not to increase virus
virulence but rather to counteract host defenses to promote spread
within the infected host.
144
Among picornaviruses that possess an L protein, the L presents
considerable diversity as regards both sequence and function (for
review, see ref. 144). For instance, the aphtovirus L protein has
catalytic activity,
145 while that of cardiovirus does not. Even
among cardioviruses there are noticeable differences. The L
protein is one of the proteins that displays the greatest divergence
between TMEV and EMCV (35% amino acid identity).
146 The
EMCV L protein is 67 amino acids long and contains an atypical
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residues Thr47
147 and Tyr41,
148 two residues that are not
conserved in the TMEV L protein. Moreover, EMCV L lacks
the Ser/Thr-rich C-terminal domain present in the TMEV L.
Even if EMCV L protein is devoid of any known enzymatic
activity, in contrast to that of aphtovirus, it appears to suppress
interferon production
149 and impair nucleo-cytoplasmic traffick-
ing through the binding of Ran-GTPase (Ras-related nuclear
-GTPase required for the RNA and protein translocation through
the nuclear pores) and through phosphorylation and inactivation
of nucleoporins.
150-154
Substitution of the L protein of TMEV by that of Mengovirus
showed that even if these two L proteins display very little
similarity (less than 40% identity), they were both able to inhibit
transcription of type I interferon, cytokine and chemokine genes,
to interfere with nucleocytoplasmic trafficking of host-cell
proteins
146 and to inhibit infection-induced stress granule
assembly.
155 Stress granules are cytosolic aggregates of stalled
translation preinitiation complexes that form in cells exposed to
various environmental stresses. They are thought to play a role in
translation inhibition during stress, through sequestration of
cellular mRNA. When cells recover from stress, stress granules
disperse and mRNA can be released for effective translation or
targeted to processing bodies (P-bodies). These studies indicate
that the L protein counteracts host responses through different
pathways, a function that appears to be conserved among different
cardiovirus strains and species. Both TMEV and PV have been
recently described to inhibit stress granule assembly. However, it
is yet to be determined whether EMCV infection induces stress
granule formation that is then inhibited by the EMCV L protein.
Whether the L protein of EMCV assumes all the functions
described when expressed by a TMEV recombinant virus is
uncertain. Kinetic analyses of the activity of the EMCV L protein
within the context of TMEV recombinant viruses indicate that
the L protein of EMCV acts faster than that of TMEV, but that
this was deleterious for the recombinant. It should be noted
that EMCV replicates faster than TMEV.
This raised the hypothesis that L proteins of TMEV and
EMCV diverged during evolution to adapt to the different levels
of replication fitness displayed by these viruses.
146
TMEV strains are divided in two subgroups, GVDII is highly
neurovirulent, inducing acute fatal polioencephalomyelitis in
mice. The TO subgroup in contrast are strains that induce non-
fatal polioencephalomyelitis followed by chronic inflammatory
demyelination with virus persistence in the spinal cord (for review,
see refs. 3 and 4). It has been shown that strains from the TO
subgroup of TMEV possess an out of frame L* which inhibits
apoptosis, while the TMEV L present in all subgroup induces
it.
156 The L* is believed to play an important role for the viral
persistence. In contrast, EMCV that is not known as a persistent
virus, has only one L protein, as described above, that has been
shown to be required to inhibit apoptosis.
Indeed it has been demonstrated that mutation in the L protein
of Mengovirus abrogates its ability to inhibit apoptosis during
viral infection.
77 (The inhibition of apoptosis during EMCV
infection is further discussed below.)
The EMCV L protein is one of the best characterized proteins
of EMCV. It is a multifunctional protein that interferes with
many host cell functions. Such interference is likely to be
deleterious for the infected cell, and probably for the host, as well.
In vivo studies to define whether mutation in the L protein of
EMCV would lead to attenuation of virulence are lacking at
present. Indeed, an in vivo study would be required to determine
unequivocally whether the L protein should be considered to be a
virulence factor of EMCV.
The 2A protein, represented in Figure3, is considered to be a
second viral security protein of EMCV.
144 It is a small protein of
17kDa, 143 amino acids in length and highly basic, and which,
unlike the 2A protein of enterovirus, is not a protease. However,
during elongation, prior to the synthesis of the 3C protease, the
2A and 2B proteins are not linked. This interruption in the
polyprotein sequence is the consequence of ribosome skipping at
the NPG(P) peptide sequence.
157 This interruption, also called
“StopGo” translation, is thought to be caused by an interaction
between the 2A peptide and the exit tunnel of the ribosome,
preventing the interaction of the ribosome with Pro-tRNA
(proline is the first amino acid of the 2B protein).
Upon infection with most picornaviruses, host protein
synthesis is shut off.
30 This function has been attributed to the
2A protein of EMCV, since partial deletion of this protein result
in maintenance of cellular mRNA translation.
55 The shut-off of
host protein synthesis that occurs during EMCV infection is not
as rapid or extensive as during PV infection.
33 Indeed, in the case
of EMCV, it is thought to stem from competition between cap-
and IRES-dependent translation, rather than to be a definitive
shut-off.
16,158 Several non-exclusive mechanisms involving the 2A
protein have been described.
The inhibition of cap-dependent translation could be due to
the activation of a translational inhibitor. It has been shown that
dephosphorylation of 4E-BP1 triggers the sequestration of eIF4E
and inhibits cap-dependent translation. EMCV 2A protein
expression in BHK-21 cells triggers 4E-BP1 hypophosphoryla-
tion,
55 and thus could contribute to the inhibition of cap-
dependent translation. This mechanism, however, has not been
confirmed in HeLa and L cell types,
159 where protein synthesis
shut-off has also been observed.
Another possibility is that this shut-off is achieved by the
interaction of the 2A protein with the translation initiation factor
eIF4E. An eIF4E binding site has been located between the amino
acids 126–134 of the 2A protein.
159 This interaction might
impede eIF4E binding to eIF4G (interactions eIF4E-, eIF4G- and
eIF4A are required for initiation of cap-dependent translation).
However, alteration of the 2A-eIF4E interaction by introduction
of point mutations in the 2A protein is not able to restore normal
protein synthesis levels.
159
Early after EMCV infection, the 2A protein is localized in the
nucleoli, owing to its nuclear localization signal (NLS),
159 and
associates with the nascent ribosomal subunit.
160,161 Mutations
introduced in the NLS have been shown to decrease inhibition of
cap-dependent translation. In the cytosol, the 2A protein interacts
with the 40S ribosomal subunit.
158,162 This association is believed
to induce preferential use of IRES-dependent templates (rather
www.landesbioscience.com Virulence 361than capped mRNA). Of note, it has been reported that the 2A
protein of EMCV binds RNAs but the functional significance of
this interaction remain to be established.
Recently, we have shown that BHK-21 cells infected with
EMCV bearing a large deletion in the 2A protein undergo
apoptosis through caspase 3 activation, and that induction of
apoptosis is independent of the ability of 2A to shut off cap-
dependent translation.
78 Thus the 2A protein of EMCV is
important in inhibiting apoptosis.
In addition, deletion in the 2A protein profoundly affects
EMCV virulence in vitro and in vivo.
55,78 Our study also showed
that, despite a large deletion within the 2A protein of EMCV, this
virus was still able to infect and replicate in mice. Nevertheless, the
virus no longer induced any clinical symptoms, while the wild type
virus led to death in all mice within a week. These results were
obtained for two different EMCV strains, one that originally
induced myocarditis inpigsand another that causedabortion.Thus
the EMCV 2A protein is required for viral pathogenesis in mice.
In conclusion, the EMCV 2A protein is important for the virus
in counteracting the host defense, as D2A viruses do not inhibit
cap-dependent translation,
55,159 are unable to inhibit apoptosis in
vitro and are no longer pathogenic in vivo.
78 The 2A protein thus
well deserves to be considered a virulence factor or a “viral security
protein.”
144
Inhibition of apoptosis. The EMCV has mainly been described
as a lytic virus that undergoes “necrotic” cell death. Interestingly,
observation of viruses bearing modified 2A and L protein
(EMCV
78 and Mengo,
77 respectively) has shown that the infection
was responsible for apoptotic cell death. These studies suggest that
EMCV has evolved to be able to counteract cell host defense
through the inhibition of programmed cell death. The exact
mechanisms by which the L and 2A protein may interfere with
apoptosis remain to be characterized.
Apoptosis is considered to be a common cellular defense
mechanism in many viral infections. This process can prevent
generation and spread of viral progeny.
Of note, apoptotic cells have been detected during wild-type
EMCV infection in vivo.
121,163,164 However, it remains unclear
whether apoptosis is a direct or indirect effect of viral infection. As
described by Buenz et al.
165 for TMEV-infected mice, the
possibility that the majority of cells undergoing apoptosis are
uninfected cannot be ruled out. Yamada et al.
164 reported that the
main source of apoptotic cells in the heart of EMCV-infected
mice appeared to be the infiltrating mononuclear cells and not the
cardiac myocytes.
However, more experiments and quantification will be required
to decipher whether induction of apoptosis during EMCV
infection in vivo results from the virus itself or through the host
response to viral infection. In favor to the hypothesis that
apoptosis is inhibited during EMCV infection in vivo, it has been
shown that inhibition of apoptosis by NFkB is required for
EMCV virulence in mice.
166
Indeed, NFkB, a transcription factor known to induce
inflammatory responses and to inhibit apoptosis, is activated
during EMCV infection.
167 Matsumory et al.
128 have shown that
NFkB activation, by induction of the inflammatory response, is
important for EMCV virulence. Thus, inhibition of apoptosis as
well as the induction of an inflammatory response might be
important factors for EMCV virulence.
Inflammatory response. The inflammatory response induced
upon infection plays a critical role in EMCV pathogenesis. As
described in the previous chapter, several studies indicate that
EMCV neurovirulence might be partly due to CD4
+ and CD8
+
T lymphocytes and macrophages.
133-135 Thus, inflammatory and
immune responses actually seem to exacerbate EMCV neuroviru-
lence. This may not be peculiar to development of neuroviru-
lence, as it has also been described for diabetes and myocarditis.
For diabetes, inoculation of high doses of EMCV induces β cell
destruction through direct infection and replication of the virus in
these cells. However, using lower doses and despite little EMCV-
induced β cell destruction, most damage is actually due to the
action of soluble IL-1β and TNFa secretion as well as the
production of iNOS from activated macrophages. Indeed,
inactivation of macrophages prior to viral infection almost
completely prevents EMC virus-induced diabetes.
137
In the early stages of infection, inflammatory responses are also
detected in the heart, where high levels of circulating pro-
inflammatory cytokines have been measured.
126,128,168 In the heart
of EMCV-infected mice expression of cytokine genes increases,
and their degree of expression correlates with the severity of
disease.
168 Thus, proinflammatory cytokines may serve to
accelerate the pathology of myocarditis, and may have a negative
influence on cardiac function.
In recent years, it has been shown that mast cells also play a
critical role in the pathogenesis of EMCV induced myocardi-
tis.
124,125,128 Mast cells are powerful producers of multiple
cytokines and chemical mediators. Mast cells are considered to
be part of the immune system; they present numerous similarities
with basophils, but are located in tissues, including the heart.
Upon infection of mast cell-deficient mice with EMCV, along
with a decrease in production of intracardiac IL-1β, IL-6, TNFa
and NO, mice present attenuated myocardial necrosis, diminished
cellular infiltration and improved survival rate.
124-128 Although
EMCV virulence is attenuated when immune and inflammatory
responses are downregulated; no significant effect on viral
replication has been noted.
126,128
Indeed, NFkB is activated during EMCV infections and leads
to the expression of many cytokines. Moreover, inhibition of
NFkB upon EMCV infection in mice lowered the mortality of
the animals, attenuated necrosis and cellular infiltration, and
decreased the production of IL-1β, IL-6, TNFa and NO in
mouse heart.
126,128 In agreement with these observations, two
previous studies indicated that mice lacking the p50 subunit of
NFkB more readily survived EMCV infection.
166,169 In addition,
it has been reported that the circulating TNFa level is increased in
mice infected with EMCV, and that pre-treatment with an anti-
TNFa antibody attenuated myocardial injury and decreased
mortality in the acute stage.
170 Another group, however, using
TNFa knockout mice, reported that TNFa plays a protective role
in acute viral myocarditis in mice.
129 These conflicting results
might arise from the fact that indeed, an efficient immune system
is primordial for elimination of the virus, but an excessive
362 Virulence Volume 3 Issue 4cytokine storm might be deleterious for the host, as is well-
documented in sepsis, for instance.
Altogether, the literature suggests that a strong inflammatory
response is of benefit to EMCV virulence. Therefore, one could
assume that blocking intracellular protein trafficking would not be
advantageous for the virus, since it could decrease cytokine
secretion. Indeed, 2B and 3A proteins of PV block ER-to-Golgi
trafficking, although the 2B and 3A proteins of EMCV do
not.
44,47,48 It has not as yet been determined whether EMCV
2BC, like FMDV 2BC, possesses this ability.
50 It is tempting to
suggest that EMCV does not inhibit cell protein trafficking
because inflammatory and immune responses are advantageous to
its virulence.
The RNA-sensing receptors MDA-5 and RIG-I can be
specifically activated by distinct viruses and induce an antiviral
response. EMCV exclusively activates MDA-5. Both the EMCV
3C
pro and caspases are supposed to be responsible for the
degradation of RIG-I upon EMCV infection.
39 Of note, RIG-I is
also cleaved in Poly(I:C) treated cells.
39
EMCV is able to inhibit regulatory T cell (Treg) function in an
antigen presenting cell (APC)-independent manner, but requires
that both Treg and effector T cells are simultaneously stimulated
through MDA-5.
171 The major function of Treg is to down-
regulate the immune response, mainly through the secretion of
IL-10, a known anti-inflammatory cytokine. Indeed, it has also
been reported that IL-10 expression in EMCV infected mice
suppresses the induction of IL-1β and iNOS genes, attenuates
myocardial injury and prolongs the survival of mice.
172
In addition, it has recently been described that the EMCV
attachment to the CCR5 receptor suffices to induce production of
inflammatory cytokines in macrophages within 30 min. In this
study, they made the intriguing observation that the virus does
not need to enter the macrophage to promote inflammation.
173
However, they showed that EMCV-infected CCR5-deficient
mice produce less iNOS and COX-2, more TNFa and have a
7-fold higher viral RNA load. They propose that the CCR5-
induced inflammatory response favors the control of virus spread.
No information, however, was provided regarding mouse survival
and disease evolution.
All together these data suggest that proinflammatory cytokine
production and inflammatory and immune responses are
important factors in EMCV virulence in mice. There might be
a delicate balance between the beneficial antiviral effect of
cytokines and the deleterious effects associated with the cytokine-
induced inflammatory responses, which may determine disease
development following EMCV infection.
As previously discussed, it has been shown that EMCV induces
lytic cell death and inhibits apoptosis, at least in vitro. Yet, it is
known that in vivo, lytic cell death gives rise to a greater
inflammatory response than apoptosis.
174 The inflammatory
response seems to exacerbate EMCV virulence instead of shut it
down (discussed above). In addition, inhibition of apoptosis by
NFkB has been shown to be required for pathogenesis during
EMCV infection in mice.
128,166 It has also been reported that a
virus deleted in 2A, which was no longer able to inhibit
apoptosis in vitro, was no longer pathogenic for mice in vivo.
78
Thus, both inhibition of apoptosis and induction of the
inflammatory response might be important factors for EMCV
virulence. In this study, however, it cannot be ruled out that
delay in virus release may be important for virus attenuation.
This delay could actually correlate with apoptotic cell death.
Indeed, necrotic cell death leads to a massive release of virus that
is able to spread and invade the host CNS. In contrast, during
apoptosis the cell membranes are not permeabilized, which may
constrain virus to confined apoptotic bodies. Apoptotic cells are
known to attract phagocytic cells. Thus virus might be retained
in these cells and be phagocytosed, without induction of a strong
inflammatory response. Thus there might be a link between the
defect in virus release, the non-inhibition of apoptosis and the
fact that the deleted 2A virus was not able to spread throughout
the CNS.
Conclusion
The EMCV is a rapidly lytic virus that does not persist in hosts in
most cases. It induces sudden death, myocarditis, encephalitis,
nervous disorders and diabetes. Its pathogenicity and the diseases
induced depend on viral and host factors. The L and 2A proteins
are the two major known virulence factors of EMCV, but
understanding of some of their functions at the molecular or host
levels is limited. However, EMCV pathogenesis seems to correlate
with a strong and uncontrolled inflammatory response that may
contribute to EMCV virulence in vivo. Many studies have
described an improvement in mouse survival when different
components of the immune response are selectively down-
modulated. Nevertheless, in other studies the inflammatory
response was shown to be protective. This apparent contradiction
might reflect a delicate balance between the beneficial effect of the
antiviral response and the deleterious effect of a strong
inflammatory response. In this balance, inhibition of apoptosis
could be one of the major viral activities to tip the scale toward the
deleterious side. Indeed, studies using 2A deleted virus suggest a
link between viral release, anti-apoptotic activity, inflammatory
response and the pathogenicity of EMCV. Further investigations
are needed to elucidate how EMCV may manipulate cell death
processes to improve viral dissemination, knowledge that could
make a major contribution to the understanding of the biology of
EMCV.
Although EMCV rarely induces severe clinical symptoms in
humans, its worldwide distribution and its wide host range, as
well as the biological characteristics of RNA viruses and the use of
heart pigs for xenografts, all call for on-going vigilance and
improvement of our knowledge of this virus.
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